Heather Giles
Directeur Général chez Vapogenix, Inc.
Postes actifs de Heather Giles
Sociétés | Poste | Début | Fin |
---|---|---|---|
Vapogenix, Inc.
Vapogenix, Inc. Medical/Nursing ServicesHealth Services Vapogenix, Inc. operates as a clinical stage company which develops a new class of non-narcotic analgesics for localized pain. Its products are formulated volatile anesthetics; currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. The company was founded by Allen W. Burton, Phillip C. Phan and Danguole Spakevicius Altman in November 2007 and is headquartered in Houston, TX. | Directeur/Membre du Conseil | 01/01/2009 | - |
Directeur Général | 01/07/2017 | - | |
Directeur Technique/Scientifique/R&D | 01/01/2009 | - | |
President | 01/07/2017 | - | |
British Pharmacological Society
British Pharmacological Society Investment Trusts/Mutual FundsMiscellaneous The British Pharmacological Society is a charity and membership organization that aims to promote and advance the field of pharmacology. The private company is based in London, UK. The British company leads the way in researching and applying pharmacology worldwide. The company was founded in 1931. Rachel Lambert-Forsyth has been the CEO of the company since 2020. | Corporate Officer/Principal | - | - |
RNIB Charity
RNIB Charity Miscellaneous Commercial ServicesCommercial Services RNIB Charity is a non-profit charitable organization that provides support and advice to people with sight problems. The non-profit company is based in London, UK. The British company was founded in 2014. | Directeur/Membre du Conseil | 02/05/2019 | - |
Historique de carrière de Heather Giles
Anciens postes connus de Heather Giles
Sociétés | Poste | Début | Fin |
---|---|---|---|
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | Corporate Officer/Principal | 13/04/2010 | 01/09/2012 |
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | Corporate Officer/Principal | 01/11/2001 | 29/04/2011 |
GlaxoWellcome /Pharmocology Unit/ | Corporate Officer/Principal | 01/01/1995 | 01/01/2000 |
GSK PLC | Corporate Officer/Principal | - | - |
Formation de Heather Giles
University of London | Undergraduate Degree |
University of Oxford | Doctorate Degree |
Statistiques
Internationale
Royaume-Uni | 7 |
Etats-Unis | 4 |
Opérationnelle
Corporate Officer/Principal | 5 |
Director/Board Member | 2 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 4 |
Commercial Services | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
GSK PLC | Health Technology |
Entreprise privées | 6 |
---|---|
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | Health Technology |
GlaxoWellcome /Pharmocology Unit/ | Commercial Services |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | Health Technology |
Vapogenix, Inc.
Vapogenix, Inc. Medical/Nursing ServicesHealth Services Vapogenix, Inc. operates as a clinical stage company which develops a new class of non-narcotic analgesics for localized pain. Its products are formulated volatile anesthetics; currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. The company was founded by Allen W. Burton, Phillip C. Phan and Danguole Spakevicius Altman in November 2007 and is headquartered in Houston, TX. | Health Services |
British Pharmacological Society
British Pharmacological Society Investment Trusts/Mutual FundsMiscellaneous The British Pharmacological Society is a charity and membership organization that aims to promote and advance the field of pharmacology. The private company is based in London, UK. The British company leads the way in researching and applying pharmacology worldwide. The company was founded in 1931. Rachel Lambert-Forsyth has been the CEO of the company since 2020. | Miscellaneous |
RNIB Charity
RNIB Charity Miscellaneous Commercial ServicesCommercial Services RNIB Charity is a non-profit charitable organization that provides support and advice to people with sight problems. The non-profit company is based in London, UK. The British company was founded in 2014. | Commercial Services |
- Bourse
- Insiders
- Heather Giles
- Expérience